Anebulo Pharmaceuticals, Inc. (ANEB) [Rocket]

In millions, except per share items	Mar-31-23	Jun-30-22	Mar-31-22	Dec-31-21	Sep-30-21	Jun-30-21	Mar-31-21
	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q
Revenues		0.0	0.0	0.0	0.0	0.0	0.2
Revenue growth			-100.0%
Cost of goods sold		0.0	0.0	0.0	0.0	0.0	0.2
Gross profit		0.0	0.0	0.0	0.0	0.0	0.0
Gross margin							-15.6%
Selling, general and administrative [+]		3.9	3.4	2.7	2.0	1.4	0.7
General and administrative		3.9	3.4	2.7	2.0	1.4	0.7
Research and development		3.0	3.7	3.0	3.0	2.3	0.5
Other operating expenses					0.0
EBIT [+]		-6.8	-7.0	-5.7	-4.9	-3.6	-1.3
EBIT growth		88.8%	435.0%
EBIT margin							-871.0%
Interest expense, net [+]		0.0				0.0
Interest expense						0.0
Interest income		0.0				0.0
Other income (expense), net [+]		0.0	-26.6	-26.6	-26.6	-26.6	0.0
Other			0.0			0.0
Pre-tax income		-6.8	-33.6	-32.3	-31.6	-30.2	-1.3
Income taxes		0.0	0.0	0.0	0.0	0.0	0.0
Tax rate		0.0%	0.0%	0.0%	0.0%	0.0%	-0.3%
Net income		-6.8	-33.6	-40.5	-39.8	-38.5	-9.5
Net margin							-6349.2%

Basic EPS [+]		($0.29)	($1.61)	($2.21)	($2.53)	($2.98)	($0.76)
Growth		-90.2%	110.8%
Diluted EPS [+]		($0.29)	($1.61)	($2.21)	($2.53)	($2.98)	($0.76)
Growth		-90.2%	110.8%

Shares outstanding (basic) [+]		23.3	20.9	18.3	15.7	12.9	12.5
Growth		81.0%	67.4%
Shares outstanding (diluted) [+]		23.3	20.9	18.3	15.7	12.9	12.5
Growth		81.0%	67.4%

EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges.